BioSpace News Archive

Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.

Promising data from the DREAMM-7 and DREAMM-8 trials have revitalized GSK’s blockbuster goals for its antibody-drug conjugate Blenrep, positioned as a second-line treatment for multiple myeloma.

This week’s news ranged from BioSpace’s on-the-ground updates from DIA to safety concerns in clinical trials to BIOSECURE Act updates to new projections that the GLP-1 market could top $100 billion within 10 years.

The next six months for the FDA are primed to be as groundbreaking as the first six, with Eli Lilly’s donanemab and Lykos Therapeutics’ MDMA-assisted PTSD therapy on the docket, among others.

Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.

Bioretec Ltd, a pioneer in biodegradable orthopedic implants, has, as of June 17, 2024, appointed Frank Sarcone as Vice President of Sales for the United States and a member of Bioretec’s Management Team.

Shanghai Junshi Biosciences Co., Ltd announced that the National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with etoposide plus platinum for the first-line treatment of extensive-stage small cell lung cancer.

Alvotech and Advanz Pharma announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of Alvotech’s proposed biosimilar to Eylea®.

Spektar Therapeutics FZCO and Altus Formulation Inc. announced the launch of Spektus Pharma Inc. a new Canadian specialty pharma company developing patent-protected value-added medicines for the growing CNS segment.

Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.